Outputs (23)

A new immunomagnetic microfluidic device for characterizing EGFR mutations in circulating tumor cells from patients withnon-small cell lung cancer (2024)
Journal Article
Ogidi, N. O., Lind, M. J., & Greenman, J. (online). A new immunomagnetic microfluidic device for characterizing EGFR mutations in circulating tumor cells from patients withnon-small cell lung cancer. Tumor Discovery, Article 3987. https://doi.org/10.36922/td.3987

ncorporating precision oncology into cancer management has begun to improve clinical outcomes. Accurate sampling techniques that detect molecular aberrations are crucial for effective implementation. Circulating tumor cells (CTCs), derived from prima... Read More about A new immunomagnetic microfluidic device for characterizing EGFR mutations in circulating tumor cells from patients withnon-small cell lung cancer.

Determination of epithelial growth factor receptor mutations in circulatory tumour cells from non-small cell lung cancer patients isolated using a novel microfluidic device (2022)
Thesis
Ogidi, N. O. Determination of epithelial growth factor receptor mutations in circulatory tumour cells from non-small cell lung cancer patients isolated using a novel microfluidic device. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4270004

Patients with epidermal growth factor receptor (EGFR) sensitizing mutations in non small cell lung cancer (NSCLC) receive benefit from Tyrosine Kinase inhibitors. Accurate selection of patients before treatment is highly dependent on precise molecula... Read More about Determination of epithelial growth factor receptor mutations in circulatory tumour cells from non-small cell lung cancer patients isolated using a novel microfluidic device.

Exploring hypoxic biology to improve radiotherapy outcomes (2022)
Journal Article
Li, C., Wiseman, L., Okoh, E., Lind, M., Roy, R., Beavis, A., & Monteiro dos Santos Pires, I. (2022). Exploring hypoxic biology to improve radiotherapy outcomes. Expert Reviews in Molecular Medicine, 24, Article E21. https://doi.org/10.1017/erm.2022.14

Ionising radiotherapy is a well-established, effective cancer treatment modality, whose efficacy has improved with the application of newer technological modalities. However, patient outcomes are governed and potentially limited by aspects of tumour... Read More about Exploring hypoxic biology to improve radiotherapy outcomes.

The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma (2019)
Journal Article
Oguh-Olayinka, L., Agarwal, V., Ranatunge, D., Campbell, A., Laufer, S., Cawkwell, L., & Lind, M. J. (2020). The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma. Pathology and Oncology Research, 26(2), 985-995. https://doi.org/10.1007/s12253-019-00652-x

Advanced malignant pleural mesothelioma (MPM) has an extremely poor prognosis with limited chemotherapy options, therefore the identification of new therapeutic targets would aid in disease management. Arachidonic acid is metabolised by cyclooxygenas... Read More about The investigation of lipoxygenases as therapeutic targets in malignant pleural mesothelioma.

MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma (2017)
Journal Article
Moody, H. L., Lind, M. J., & Maher, S. G. (2017). MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma. Molecular Therapy - Nucleic Acids, 8(15 September 2017), 317-329. https://doi.org/10.1016/j.omtn.2017.07.001

Malignant pleural mesothelioma (MPM) is associated with an extremely poor prognosis, and most patients initially are or rapidly become unresponsive to platinum-based chemotherapy. MicroRNA-31 (miR-31) is encoded on a genomic fragile site, 9p21.3, whi... Read More about MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma.

EGFR and related therapeutic targets in malignant pleural mesothelioma (2016)
Thesis
Oguh, L. I. EGFR and related therapeutic targets in malignant pleural mesothelioma. (Thesis). Hull York Medical School, the University of Hull and the University of York. https://hull-repository.worktribe.com/output/4221787

Introduction
Malignant pleural mesothelioma (MPM) is a rare but aggressive disease and the current first line treatment is associated with a survival rate of 40%. There is currently no second line therapy. This study aimed to explore the expression... Read More about EGFR and related therapeutic targets in malignant pleural mesothelioma.

Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker (2014)
Journal Article
Garimella, V., Hussain, T., Agarwal, V., Radhakrishna, S., Fox, J. N., Kneeshaw, P. J., Long, E. D., Mahapatra, T. K., McManus, P. L., Lind, M. J., Drew, P. J., & Cawkwell, L. (2014). Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker. International journal of surgery, 12(8), 821-826. https://doi.org/10.1016/j.ijsu.2014.06.009

Primary tamoxifen therapy has been widely used to treat elderly women with ER-positive breast cancer in the past. Aromatase inhibitors may be more beneficial than tamoxifen when used as primary endocrine therapy in elderly patients. We aimed to retro... Read More about Clinical response to primary letrozole therapy in elderly patients with early breast cancer : possible role for p53 as a biomarker.

Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697 (2013)
Journal Article
Agarwal, V., Hodgkinson, V. C., Eagle, G. L., Scaife, L., Lind, M. J., & Cawkwell, L. (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. International Journal of Oncology, 42(3), 1088-1092. https://doi.org/10.3892/ijo.2013.1784

We have previously shown that specific COX-2 inhibitors, including DuP 697, have anti-proliferative effects on mesothelioma cells and potentiate the cytotoxicity of pemetrexed. Here, we used a novel proteomic approach to explore the mechanism of acti... Read More about Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697.

PTEN protein expression in malignant pleural mesothelioma (2012)
Journal Article
Agarwal, V., Campbell, A., Beaumont, K. L., Cawkwell, L., & Lind, M. J. (2013). PTEN protein expression in malignant pleural mesothelioma. Tumor Biology, 34(2), 847-851. https://doi.org/10.1007/s13277-012-0615-9

Malignant pleural mesothelioma is associated with poor prognosis and despite recent advances in chemotherapy, the median survival is still approximately 12 months. Loss of phosphatase and tensin homolog (PTEN) protein expression may lead to constitut... Read More about PTEN protein expression in malignant pleural mesothelioma.

Proteomic identification of putative biomarkers of radiotherapy resistance (2012)
Thesis
Scaife, L. Proteomic identification of putative biomarkers of radiotherapy resistance. (Thesis). University of Hull. https://hull-repository.worktribe.com/output/4214086

Background
Currently, tumour response to radiotherapy cannot be predicted meaning that those patients with tumours resistant to the therapy endure the harmful side effects associated with ionising radiation in the absence of therapeutic gain. The ai... Read More about Proteomic identification of putative biomarkers of radiotherapy resistance.